Form 4: Aligos Therapeutics Director, Bridget Martell, Reports Stock Option Grant

Director Bridget Martell reports receiving a stock option grant for 60,000 shares of Aligos Therapeutics, Inc.

Summary

• On June 27, 2024, Bridget Martell, a director of Aligos Therapeutics, Inc. (ALGS), reported a transaction involving derivative securities.
• Martell was granted a stock option to purchase 60,000 shares of ALGS common stock at an exercise price of $0.38 per share.
• The options vest on the earlier of June 27, 2025, or immediately prior to the annual meeting in 2025, subject to continuous service to the Issuer through such vesting date.
• Following the transaction, Martell directly owns 60,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it simply reports a standard stock option grant to a director, which is a common practice.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.

Key Dates